Inhalte
Startseite > Köpfe am DRFZ > Prof. Dr. Julia Polansky

Prof. Dr. Julia Polansky

Programmbereich 4, PB 4 – Translationale Rheumatologie

Gruppenleitung: Immun-Epigenetik

Liaisonarbeitsgruppe mit Charité - BIH-Center for Regenerative Therapies, BCRT

+49 30 450 524 197

julia.polansky-biskup@bih-charite.de

Scientific Background

Since 2019
Professor for Immuno-Epigenetics at Charité Universitätsmedizin Berlin; group leader at the BIH Center for Regenerative Therapies (BCRT) and at the German Rheumatism Research Centre Berlin (DRFZ), Berlin, Germany

2017 – 2019
Junior-Group leader at BCRT, Berlin, Germany

2012 – 2018
Project leader at the German Rheumatism Research Center (DRFZ), Berlin, Germany

2010 – 2012
Postdoc at the Leibniz-Center Borstel, Germany

2006 – 2009
PhD student at Humboldt-Universität zu Berlin, Berlin, Germany

2004 – 2005
Guest scientist Harvard Medical School, Boston, MA, USA

2006 – 2009
Humboldt-Universität zu Berlin: Doctorate, summa cum laude

2000 – 2005
University of Hamburg and University of Bremen: Diploma in Biochemistry

Since 2023
Deputy speaker of the steering committee of the BCRT

Since 2021
Co-Speaker of the BIH Research Section ‘Advanced and Personalized Therapies’

Since 2019
Member of the steering committee of the BIH Center for Regenerative Therapies (BCRT)

Since 2016
Member in appointment committees for professorships (‘Berufungskommission’), examination boards for PhD graduations, thesis advisory committees (TACs) for PhD students

Since 2016
PI in the ‘Leibniz Science Campus for Chronic Inflammatory diseases’ in Berlin

Since 2015
Associated faculty member at the Center of Infection Biology and Immunity (ZIBI), Berlin

German Society for Immunology (DGfI), German Society for Rheumatology and Clinical Immunology (DGRh)

Since 2020
Listed in ‘AcademiaNet: Profiles of Leading Women Scientists’

2019
ERC Starting Grantee

2006 – 2009
Stipend of the International Max Planck Research School for Infectious Diseases and Immunology, Berlin

2005
Heinz-Dürr Fellowship (Carl-Zeiss-Foundation)

2004 – 2005
Stipend of the German Academic Exchange Service (DAAD)

2003 – 2004
Stipend of the German National Academic Foundation (Studienstiftung des deutschen Volkes)

TOP 5 PUBLICATIONS

The life-saving benefit of dexamethasone in severe COVID-19 is linked to a reversal of monocyte dysregulation Knoll R, Helbig ET, Dahm K, Bolaji O, Hamm F, Dietrich O, van Uelft M, Müller S, Bonaguro L, Schulte-Schrepping J, Petrov L, Krämer B, Kraut M, Stubbemann P, Thibeault C, Brumhard S, Theis H, Hack G, De Domenico E, Nattermann J, Becker M, Beyer MD, Hillus D, Georg P, Loers C, Tiedemann J, Tober-Lau P, Lippert L, Millet Pascual-Leone B, Tacke F, Rohde G, Suttorp N, Witzenrath M; CAPNETZ Study Group; Pa-COVID-19 Study Group; Saliba AE, Ulas T, Polansky JK, Sawitzki B, Sander LE, Schultze JL, Aschenbrenner AC, Kurth F. The life-saving benefit of dexamethasone in severe COVID-19 is linked to a reversal of monocyte dysregulation. Cell. 2024 Aug 8;187(16):4318-4335.e20. doi: 10.1016/j.cell.2024.06.014. Epub 2024 Jul 3. PMID: 38964327.
The enhancer landscape predetermines the skeletal regeneration capacity of stromal cells Hochmann S, Ou K, Poupardin R, Mittermeir M, Textor M, Ali S, Wolf M, Ellinghaus A, Jacobi D, Elmiger JAJ, Donsante S, Riminucci M, Schäfer R, Kornak U, Klein O, Schallmoser K, Schmidt-Bleek K, Duda GN, Polansky JK, Geissler S, Strunk D. The enhancer landscape predetermines the skeletal regeneration capacity of stromal cells. Sci Transl Med. 2023 Mar 22;15(688):eabm7477. doi: 10.1126/scitranslmed.abm7477. Epub 2023 Mar 22. PMID: 36947595.
Targeted De-Methylation of the FOXP3-TSDR Is Sufficient to Induce Physiological FOXP3 Expression but Not a Functional Treg Phenotype Kressler C, Gasparoni G, Nordström K, Hamo D, Salhab A, Dimitropoulos C, Tierling S, Reinke P, Volk HD, Walter J, Hamann A, Polansky JK. Targeted De-Methylation of the FOXP3-TSDR Is Sufficient to Induce Physiological FOXP3 Expression but Not a Functional Treg Phenotype. Front Immunol. 2021 Jan 7;11:609891. doi: 10.3389/fimmu.2020.609891. PMID: 33488615; PMCID: PMC7817622.
Epigenomic Profiling of Human CD4+ T Cells Supports a Linear Differentiation Model and Highlights Molecular Regulators of Memory Development Durek P, Nordström K, Gasparoni G, Salhab A, Kressler C, de Almeida M, Bassler K, Ulas T, Schmidt F, Xiong J, Glažar P, Klironomos F, Sinha A, Kinkley S, Yang X, Arrigoni L, Amirabad AD, Ardakani FB, Feuerbach L, Gorka O, Ebert P, Müller F, Li N, Frischbutter S, Schlickeiser S, Cendon C, Fröhler S, Felder B, Gasparoni N, Imbusch CD, Hutter B, Zipprich G, Tauchmann Y, Reinke S, Wassilew G, Hoffmann U, Richter AS, Sieverling L; DEEP Consortium; Chang HD, Syrbe U, Kalus U, Eils J, Brors B, Manke T, Ruland J, Lengauer T, Rajewsky N, Chen W, Dong J, Sawitzki B, Chung HR, Rosenstiel P, Schulz MH, Schultze JL, Radbruch A, Walter J, Hamann A, Polansky JK. Epigenomic Profiling of Human CD4+ T Cells Supports a Linear Differentiation Model and Highlights Molecular Regulators of Memory Development. Immunity. 2016 Nov 15;45(5):1148-1161. doi: 10.1016/j.immuni.2016.10.022. PMID: 27851915.
DNA methylation controls Foxp3 gene expression Polansky JK, Kretschmer K, Freyer J, Floess S, Garbe A, Baron U, Olek S, Hamann A, von Boehmer H, Huehn J. DNA methylation controls Foxp3 gene expression. Eur J Immunol. 2008 Jun;38(6):1654-63. doi: 10.1002/eji.200838105. PMID: 18493985.

Immun-Epigenetik

AG Polansky

Projekte

Go to end of slider
Mehr zeigen